Summary: Also, the sales outlook for the blockbuster diabetes drug, Mounjaro, and the debate on whether unions are bad for investors.
Summary: Also, the sales outlook for the blockbuster diabetes drug, Mounjaro, and the debate on whether unions are bad for investors.